Download MODELOS CLINICO-DOSIMETRICOS PREDICTIVOS DEL CONTROL BIOQUIMICO DEL CANCER DE PROSTATA ORGANO-CONFINADO TRATADO MEDIANTE

MODELOS CLINICO-DOSIMETRICOS
PREDICTIVOS DEL CONTROL BIOQUIMICO
DEL CANCER DE PROSTATA
ORGANO-CONFINADO TRATADO MEDIANTE
IMPLANTES RADIACTIVOS PERMANENTES
Alfredo Polo Rubio
Universidad de Barcelona
Departamento de Ciencias Clínicas
Año 2007
)0)306.9(-0*(:
2.
3.
10.
12.
13.
15.
16.
19.
22.
6SZVU ;9 (+(4Ž ([SHZ KL HUH[VTxH O\THUH )HYJLSVUH! 4(::65 >PSSPHTZ >PSRPUZ,ZWH|H:(" Potenziani JC. Historia de la Urología (y II); 2006.
McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol
1968;49:347-357.
>PSSPHTZ73>HY^PJR9.YH`(UH[VTxH)HYJLSVUH!:HS]H[" (SILY[ZLU 7* -Y`IHJR +. :[VYLY ),, et al. 3VUN[LYT Z\Y]P]HS HTVUN TLU ^P[O
conservatively treated localized prostate cancer. Jama 1995;274:626-631.
*OVKHR .> ;OPZ[LK 9( .LYILY .:, et al. Results of conservative management of
clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
4\YWO`41VOUZ[VU*>OLSHU7, et al. Changing trends in prostatic cancer. BJU Int
1999;83:786-791.
0ZHHJZ>+L4HYaV(5LSZVU>.-VJ\ZVUWYVZ[H[LJHUJLYCancer Cell 2002;2:113116.
:JHYKPUV7;>LH]LY9/\KZVU4(,HYS`KL[LJ[PVUVMWYVZ[H[LJHUJLYHum Pathol
1992;23:211-222.
Barrett-Connor E, Garland C, McPhillips JB, et al. A prospective, population-based
study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990;50:169173.
2`WYPHUV\50ZHHJZ1;(J[P]H[PVUVMWYVNYHTTLKJLSSKLH[OPU[OLYH[]LU[YHSWYVZ[H[L
after castration. Endocrinology 1988;122:552-562.
Thompson IM, Goodman PJ, Tangen CM, et al. ;OL PUÅ\LUJL VM ÄUHZ[LYPKL VU [OL
development of prostate cancer. N Engl J Med 2003;349:215-224.
Ross R, Bernstein L, Judd H, et al.:LY\T[LZ[VZ[LYVULSL]LSZPUOLHS[O``V\UNISHJR
HUK^OP[LTLUJ Natl Cancer Inst 1986;76:45-48.
9VZZ92)LYUZ[LPU33VIV9(, et al.HSWOHYLK\J[HZLHJ[P]P[`HUKYPZRVMWYVZ[H[L
JHUJLYHTVUN1HWHULZLHUK<:^OP[LHUKISHJRTHSLZLancet 1992;339:887-889.
Roach M, 3rd, Lu J, Pilepich MV, et al. Race and survival of men treated for prostate
cancer on radiation therapy oncology group phase III randomized trials. J Urol
2003;169:245-250.
Chuba PJ, Moughan J, Forman JD, et al. The 1989 patterns of care study for prostate
JHUJLY!Ä]L`LHYV\[JVTLZInt J Radiat Oncol Biol Phys 2001;50:325-334.
4J5LHS1,)VZ[^PJR+.0U[YHK\J[HSK`ZWSHZPH!HWYLTHSPNUHU[SLZPVUVM[OLWYVZ[H[L
Hum Pathol 1986;17:64-71.
,WZ[LPU107V[[LY:9;OLWH[OVSVNPJHSPU[LYWYL[H[PVUHUKZPNUPÄJHUJLVMWYVZ[H[LULLKSL
IPVWZ`ÄUKPUNZ!PTWSPJH[PVUZHUKJ\YYLU[JVU[YV]LYZPLZJ Urol 2001;166:402-410.
Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and
clinical features. J Urol 1993;150:797-802.
/HU\Z4*AHNHYZ.27VSSHJR(-HTPSPHSWYVZ[H[LJHUJLY!V\[JVTLMVSSV^PUNYHKPH[PVU
[OLYHW` ^P[O VY ^P[OV\[ HKQ\]HU[ HUKYVNLU HISH[PVU Int J Radiat Oncol Biol Phys
1999;43:379-383.
)V]H.:7HY[PU(>0ZHHJZ:+, et al. Biological aggressiveness of hereditary prostate
JHUJLY! SVUN[LYT L]HS\H[PVU MVSSV^PUN YHKPJHS WYVZ[H[LJ[VT` J Urol 1998;160:660663.
Gronberg H, Damber L, Tavelin B, et al. 5V KPMMLYLUJL PU Z\Y]P]HS IL[^LLU ZWVYHKPJ
familial and hereditary prostate cancer. Br J Urol 1998;82:564-567.
76:;:*907;<4
9,-,9,5*0(:
76:;:*907;<4
Modelos clínico-dosimetricos en braquiterapia prostática
28.
29.
32.
34.
38.
39.
43.
2\WLSPHU7(2SLPU,(>P[[L1:, et al. Familial prostate cancer: a different disease? J
Urol 1997;158:2197-2201.
2\WLSPHU7(9LKK`*(9L\[OLY(4, et al. Aggressiveness of familial prostate cancer.
J Clin Oncol 2006;24:3445-3450.
+LUUPZ 32 3`UJO *- ;VYULY 1* ,WPKLTPVSVNPJ HZZVJPH[PVU IL[^LLU WYVZ[H[P[PZ HUK
prostate cancer. Urology 2002;60:78-83.
/H`LZ9)7V[[LYU34:[YPJRSLY/, et al.:L_\HSILOH]PV\Y:;+ZHUKYPZRZMVYWYVZ[H[L
cancer. Br J Cancer 2000;82:718-725.
*HSSL,,9VKYPN\La*>HSRLY;O\YTVUK2, et al.6]LY^LPNO[VILZP[`HUKTVY[HSP[`MYVT
cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:16251638.
Calle EE, Teras LR, Thun MJ. Obesity and mortality. N Engl J Med 2005;353:21972199.
Fincham SM, Hill GB, Hanson J, et al. Epidemiology of prostatic cancer: a case-control
study. Prostate 1990;17:189-206.
/ZPUN(>4J3H\NOSPU12/Y\ILJA, et al. Tobacco use and prostate cancer: 26-year
MVSSV^\WVM<:]L[LYHUZAm J Epidemiol 1991;133:437-441.
/ZPUN(>4J3H\NOSPU12:JO\THU34, et al. Diet, tobacco use, and fatal prostate
cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res 1990;50:68366840.
Elghany NA, Schumacher MC, Slattery ML, et al. Occupation, cadmium exposure, and
prostate cancer. Epidemiology 1990;1:107-115.
.SLHZVU + ;OL =L[LYHU»Z (KTPUPZ[YH[PVU *VVWLYH[P]L <YVSVNPJ 9LZLHYJO .YV\W!
histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor.
Urologic Pathology: The Prostate. Philadelphia: Lea and Febiger; 1977. pp. 171-198.
Ruijter E, van Leenders G, Miller G, et al. Errors in histological grading by prostatic
needle biopsy specimens: frequency and predisposing factors. J Pathol 2000;192:229233.
(SSZIYVVR >* 1Y 4HUNVSK 2( 1VOUZVU 4/, et al. Interobserver reproducibility of
Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001;32:7480.
.LYILY .: *OVKHR .> +PNP[HS YLJ[HS L_HTPUH[PVU PU [OL LHYS` KL[LJ[PVU VM WYVZ[H[L
cancer. Urol Clin North Am 1990;17:739-744.
7HY[PU(>@VV1*HY[LY/), et al.;OL\ZLVMWYVZ[H[LZWLJPÄJHU[PNLUJSPUPJHSZ[HNL
HUK.SLHZVUZJVYL[VWYLKPJ[WH[OVSVNPJHSZ[HNLPUTLU^P[OSVJHSPaLKWYVZ[H[LJHUJLY
J Urol 1993;150:110-114.
Carvalhal GF, Smith DS, Mager DE, et al. Digital rectal examination for detecting prostate
JHUJLY H[ WYVZ[H[L ZWLJPÄJ HU[PNLU SL]LSZ VM UNTS VY SLZZ J Urol 1999;161:835839.
Schroder FH, van der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal
examination as a screening test for prostate cancer. Rotterdam section of the European
Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90:18171823.
)YH^LY42*OL[ULY47)LH[PL1, et al.:JYLLUPUNMVYWYVZ[H[PJJHYJPUVTH^P[OWYVZ[H[L
ZWLJPÄJHU[PNLUJ Urol 1992;147:841-845.
(YTIY\Z[LY+(7YVZ[H[LZWLJPÄJHU[PNLU!IPVJOLTPZ[Y`HUHS`[PJHSTL[OVKZHUKJSPUPJHS
application. Clin Chem 1993;39:181-195.
-PSLSSH ? 4VSPUH 9 )HSSLZ[H (4, et al. =HS\L VM 7:( WYVZ[H[LZWLJPÄJ HU[PNLU PU
[OL KL[LJ[PVU VM WYVZ[H[L JHUJLY PU WH[PLU[Z ^P[O \YVSVNPJHS Z`TW[VTZ 9LZ\S[Z VM H
multicentre study. Eur J Cancer 1996;32A:1125-1128.
Zlotta AR, Djavan B, Marberger M, et al.7YVZ[H[LZWLJPÄJHU[PNLUKLUZP[`VM[OL[YHUZP[PVU
aVUL!HUL^LMMLJ[P]LWHYHTL[LYMVYWYVZ[H[LJHUJLYWYLKPJ[PVUJ Urol 1997;157:13151321.
:VIPU3/>P[[LRPUK*;54*SHZZPÄJH[PVUVMTHSPNUHU[[\TV\YZ[OLK!>PSSL`3PZZ"
1997.
9PMRPU4+ALYOV\UP,(.H[ZVUPZ*(, et al. Comparison of magnetic resonance imaging
POSTSCRIPTUM
51.
52.
53.
54.
56.
66.
76:;:*907;<4
and ultrasonography in staging early prostate cancer. Results of a multi-institutional
cooperative trial. N Engl J Med 1990;323:621-626.
+»(TPJV (= :JOUHSS 4 >OP[[PUN[VU 9, et al. Endorectal coil magnetic resonance
PTHNPUN PKLU[PÄLZ SVJHSS` HK]HUJLK WYVZ[H[L JHUJLY PU ZLSLJ[ WH[PLU[Z ^P[O JSPUPJHSS`
localized disease. Urology 1998;51:449-454.
*OLUN.**OLU4/>OP[[PUN[VU9, et al. Clinical utility of endorectal MRI in determining
7:( V\[JVTL MVY WH[PLU[Z ^P[O IPVWZ` .SLHZVU ZJVYL 7:( #VY$ HUK JSPUPJHSS`
localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;55:64-70.
3L]YHUA.VUaHSLa1(+PVRUV(*, et al. Are pelvic computed tomography, bone scan
and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol
1995;75:778-781.
*O`IV^ZRP -4 2LSSLY 11 )LYNZ[YHSO ,1, et al. Predicting radionuclide bone scan
ÄUKPUNZPUWH[PLU[Z^P[OUL^S`KPHNUVZLK\U[YLH[LKWYVZ[H[LJHUJLY!WYVZ[H[LZWLJPÄJ
antigen is superior to all other clinical parameters. J Urol 1991;145:313-318.
3LL 5 -H^HHa 9 6SZZVU *(, et al. >OPJO WH[PLU[Z ^P[O UL^S` KPHNUVZLK WYVZ[H[L
cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat
Oncol Biol Phys 2000;48:1443-1446.
de Jong IJ, Pruim J, Elsinga PH, et al. 11C-choline positron emission tomography for
the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-38;
discussion 38-39.
de Jong IJ, Pruim J, Elsinga PH, et al.=PZ\HSPaH[PVUVMWYVZ[H[LJHUJLY^P[O*JOVSPUL
positron emission tomography. Eur Urol 2002;42:18-23.
Picchio M, Landoni C, Messa C, et al.7VZP[P]LB*DJOVSPULHUKULNH[P]LB-D-+.^P[O
positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol
2002;179:482-484.
Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission
[VTVNYHWO`MVYYLZ[HNPUNWYVZ[H[LJHUJLY!HJVTWHYPZVU^P[OB-DÅ\VYVKLV_`NS\JVZL
positron emission tomography. J Urol 2003;169:1337-1340.
)\IVSa ; >HZZVU 1/ 3\@HV ., et al. Treatments for prostate cancer in older men:
1984-1997. Urology 2001;58:977-982.
Gerber GS, Thisted RA, Scardino PT, et al.9LZ\S[ZVMYHKPJHSWYVZ[H[LJ[VT`PUTLU^P[O
clinically localized prostate cancer. Jama 1996;276:615-619.
/HU47HY[PU(>7V\UK*9, et al. Long-term biochemical disease-free and cancerZWLJPÄJ Z\Y]P]HS MVSSV^PUN HUH[VTPJ YHKPJHS YL[YVW\IPJ WYVZ[H[LJ[VT` ;OL `LHY
1VOUZ/VWRPUZL_WLYPLUJLUrol Clin North Am 2001;28:555-565.
/\SS.>9HIIHUP-(IIHZ-, et al.*HUJLYJVU[YVS^P[OYHKPJHSWYVZ[H[LJ[VT`HSVULPU
1,000 consecutive patients. J Urol 2002;167:528-534.
APUJRL / 6LZ[LYSPUN 1, )S\[L 43, et al. Long-term (15 years) results after radical
WYVZ[H[LJ[VT` MVY JSPUPJHSS` SVJHSPaLK Z[HNL ;J VY SV^LY WYVZ[H[L JHUJLY J Urol
1994;152:1850-1857.
*H[HSVUH >1 :TP[O +: *HUJLY YLJ\YYLUJL HUK Z\Y]P]HS YH[LZ HM[LY HUH[VTPJ YHKPJHS
retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol
1998;160:2428-2434.
,HZ[OHT1(:JHYKPUV7;9HKPJHSWYVZ[L[LJ[VT`0U!>HSZO7*.P[[LZ9-7LYST\[[LY
AD, et al.LKP[VYZ*HTWILSS»Z<YVSVN`7OPSHKLSWOPH!>):H\UKLYZ*VTWHU`" -V^SLY-11Y)HYY`413\@HV., et al.7H[PLU[YLWVY[LKJVTWSPJH[PVUZHUKMVSSV^\W
treatment after radical prostatectomy. The National Medicare Experience: 1988-1990
(updated June 1993). Urology 1993;42:622-629.
>HSZO 7* 7H[PLU[YLWVY[LK \YPUHY` JVU[PULUJL HUK ZL_\HS M\UJ[PVU HM[LY HUH[VTPJ
radical prostatectomy. J Urol 2000;164:242.
>HSZO7*4HYZJORL79PJRLY+, et al. Patient-reported urinary continence and sexual
function after anatomic radical prostatectomy. Urology 2000;55:58-61.
9HIIHUP-:[HWSL[VU(42H[[HU4>, et al. Factors predicting recovery of erections
after radical prostatectomy. J Urol 2000;164:1929-1934.
Quinlan DM, Epstein JI, Carter BS, et al.:L_\HSM\UJ[PVUMVSSV^PUNYHKPJHSWYVZ[H[LJ[VT`!
PUÅ\LUJLVMWYLZLY]H[PVUVMUL\YV]HZJ\SHYI\UKSLZJ Urol 1991;145:998-1002.
76:;:*907;<4
Modelos clínico-dosimetricos en braquiterapia prostática
*H[HSVUH >1 *HY]HSOHS .- 4HNLY +,, et al. Potency, continence and complication
rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433438.
*VUZLUZ\ZZ[H[LTLU[!N\PKLSPULZMVY7:(MVSSV^PUNYHKPH[PVU[OLYHW`(TLYPJHU:VJPL[`
for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys
1997;37:1035-1041.
/VY^P[a,4=PJPUP-(APHQH,3, et al.;OLJVYYLSH[PVUIL[^LLU[OL(:;96*VUZLUZ\Z
7HULSKLÄUP[PVUVMIPVJOLTPJHSMHPS\YLHUKJSPUPJHSV\[JVTLMVYWH[PLU[Z^P[OWYVZ[H[L
JHUJLY [YLH[LK ^P[O L_[LYUHS ILHT PYYHKPH[PVU (TLYPJHU :VJPL[` VM ;OLYHWL\[PJ
Radiology and Oncology. Int J Radiat Oncol Biol Phys 1998;41:267-272.
/HUSVU(3/HURZ.,:JY\[PU`VM[OL(:;96JVUZLUZ\ZKLÄUP[PVUVMIPVJOLTPJHSMHPS\YL
in irradiated prostate cancer patients demonstrates its usefulness and robustness.
American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys
2000;46:559-566.
3H^[VU*(+LZPS]PV43LL>9, et al. Results of a phase II trial of transrectal ultrasoundN\PKLKWLYTHULU[YHKPVHJ[P]LPTWSHU[H[PVUVM[OLWYVZ[H[LMVYKLÄUP[P]LTHUHNLTLU[VM
localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05).
Int J Radiat Oncol Biol Phys 2007;67:39-47.
9VHJO 4 YK /HURZ . ;OHTLZ / 1Y, et al. +LÄUPUN IPVJOLTPJHS MHPS\YL MVSSV^PUN
YHKPV[OLYHW`^P[OVY^P[OV\[OVYTVUHS[OLYHW`PUTLU^P[OJSPUPJHSS`SVJHSPaLKWYVZ[H[L
cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J
Radiat Oncol Biol Phys 2006;65:965-974.
7LYLa*(/HURZ.,3LPILS:(, et al. Localized carcinoma of the prostate (stages T1B,
;*;HUK;9L]PL^VMTHUHNLTLU[^P[OL_[LYUHSILHTYHKPH[PVU[OLYHW`Cancer
1993;72:3156-3173.
.YLJV*ALSLMZR`419HKPVOLYHW`MVYWYVZ[H[LJHUJLY(TZ[LYKHT!/HY^VVK(JHKLTPJ
Publishers; 2000.
)HNZOH^ 4( 2HWSHU 0+ *V_ 9* 7YVZ[H[L JHUJLY 9HKPH[PVU [OLYHW` MVY SVJHSPaLK
disease. Cancer 1993;71:939-952.
APL[THU(3*VLU11+HSSV^2*, et al. The treatment of prostate cancer by conventional
radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys
1995;32:287-292.
2\IHU+(LS4HOKP(4:JOLSSOHTTLY7-7YVZ[H[LZWLJPÄJHU[PNLUMVYWYL[YLH[TLU[
WYLKPJ[PVU HUK WVZ[[YLH[TLU[ L]HS\H[PVU VM V\[JVTL HM[LY KLÄUP[P]L PYYHKPH[PVU MVY
prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:307-316.
/HURZ ., /HUSVU (3 ,WZ[LPU ), et al. +VZL YLZWVUZL PU WYVZ[H[L JHUJLY ^P[O `LHYZ»MVSSV^\WInt J Radiat Oncol Biol Phys 2002;54:427-435.
7VSSHJR(/HUSVU(3/VY^P[a,4, et al. Prostate cancer radiotherapy dose response:
an update of the fox chase experience. J Urol 2004;171:1132-1136.
7VSSHJR(AHNHYZ.2:TP[O3., et al. Preliminary results of a randomized radiotherapy
KVZLLZJHSH[PVUZ[\K`JVTWHYPUN.`^P[O.`MVYWYVZ[H[LJHUJLYJ Clin Oncol
2000;18:3904-3911.
7VSSHJR(AHNHYZ.2:[HYRZJOHSS., et al. Prostate cancer radiation dose response:
results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys
2002;53:1097-1105.
ALSLMZR` 41 3LPILS :( .H\KPU 7), et al. +VZL LZJHSH[PVU ^P[O [OYLLKPTLUZPVUHS
conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol
Biol Phys 1998;41:491-500.
ALSLMZR`41-\RZA/\U[4, et al. High dose radiation delivered by intensity modulated
conformal radiotherapy improves the outcome of localized prostate cancer. J Urol
2001;166:876-881.
ALSLMZR`41-\RZA/\U[4, et al. High-dose intensity modulated radiation therapy for
prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat
Oncol Biol Phys 2002;53:1111-1116.
2\WLSPHU7(4VOHU+:3`VUZ1, et al. Higher than standard radiation doses (> or =72
.`^P[OVY^P[OV\[HUKYVNLUKLWYP]H[PVUPU[OL[YLH[TLU[VMSVJHSPaLKWYVZ[H[LJHUJLY
POSTSCRIPTUM
94.
95.
96.
98.
100.
106.
107.
Int J Radiat Oncol Biol Phys 2000;46:567-574.
Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy
for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group
trials. J Clin Oncol 2000;18:2740-2746.
)L`7*HYYPL*)LJRLUKVYM=, et al.+VZLLZJHSH[PVU^P[O+*9;PUWYVZ[H[LJHUJLY!
-YLUJO Z[\K` VM KVZL LZJHSH[PVU ^P[O JVUMVYTHS + YHKPV[OLYHW` PU WYVZ[H[L JHUJLY
preliminary results. Int J Radiat Oncol Biol Phys 2000;48:513-517.
:`TVU A .YPMÄ[O 2( 4J3H\NOSPU 7>, et al. Dose escalation for localized prostate
JHUJLY!Z\IZ[HU[PHSILULÄ[VIZLY]LK^P[O+JVUMVYTHS[OLYHW`Int J Radiat Oncol Biol
Phys 2003;57:384-390.
2\IHU+(;OHTLZ/+3L]`3), et al. Long-term multi-institutional analysis of stage
;;WYVZ[H[LJHUJLY[YLH[LK^P[OYHKPV[OLYHW`PU[OL7:(LYHInt J Radiat Oncol Biol
Phys 2003;57:915-928.
/\Y^P[a4+:JOUPLKLY34HUVSH1, et al.3HJRVMYHKPH[PVUKVZLYLZWVUZLMVYWH[PLU[Z
^P[OSV^YPZRJSPUPJHSS`SVJHSPaLKWYVZ[H[LJHUJLY!HYL[YVZWLJ[P]LHUHS`ZPZInt J Radiat
Oncol Biol Phys 2002;53:1106-1110.
2\WLSPHU 7( )\JOZIH\T 1* 9LKK` *(, et al. Radiation dose response in patients
^P[O MH]VYHISL SVJHSPaLK WYVZ[H[L JHUJLY :[HNL ;; IPVWZ` .SLHZVU # VY $ HUK WYL[YLH[TLU[ WYVZ[H[LZWLJPÄJ HU[PNLU # VY $ Int J Radiat Oncol Biol Phys
2001;50:621-625.
(YVUV^P[a 15 +H^U VM WYVZ[H[L IYHJO`[OLYHW`! Int J Radiat Oncol Biol
Phys 2002;54:712-718.
7HZ[LH\ 6 +LNYHPZ 7 +L S»LTWSVP K\ YHKP\T KHUZ SL [YHP[LTLU[ KLZ JHUJLYZ KL SH
prostate. Journal d’urologie Medicale et Chirurgicale 1913:341–366.
Young HH. The use of radium in cancer of the prostate and bladder: a presentation of
UL^PUZ[Y\TLU[ZHUKUL^TL[OVKZVM\ZLJAMA 1917:1174-1177.
Young HH. Technique of radium treatment of cancer of the prostate and seminal
vesicles. Surg Gynecol Obstet 1922;34:93-98.
Young HH. Treatment of carcinoma of the prostate. In: Young HH, Davis DM, editors.
@V\UN»Z WYHJ[PJL VM <YVSVN`! IHZLK VU H Z[\K` VM JHZLZ 7OPSHKLSWOPH! >)
Saunders; 1926. pp. 644-671.
@V\UN//>H[LYZ*(+LLWYVLU[NLUYH`HUKYHKP\T[OLYHW`PUTHSPNUHU[KPZLHZLVM
the genitourinary tract. Am J Surg 1927;2:101-125.
Barringer BS. Radium in the treatment of carcinoma of the prostate and bladder. JAMA
1916;67:1442-1445.
)HYYPUNLY):9HKP\TPU[OL[YLH[TLU[VMJHYJPUVTHVM[OLISHKKLYHUKWYVZ[H[L!9L]PL^
VMVUL`LHY»Z^VYRJAMA 1917;68:1227-1230.
Barringer BS. Radium in the treatment of prostatic carcinoma. Ann Surg 1924;8:881884.
-SVJRZ9/2LYY/+,SRPUZ/), et al. Treatment of carcinoma of the prostate by interstitial
YHKPH[PVU^P[OYHKPVHJ[P]LNVSK(\ !HWYLSPTPUHY`YLWVY[J Urol 1952;68:510-522.
-SVJRZ9/2LYY/+,SRPUZ/), et al. The treatment of carcinoma of the prostate by
PU[LYZ[P[PHSYHKPH[PVU^P[OYHKPVHJ[P]LNVSK(\ "HMVSSV^\WYLWVY[J Urol 1954;71:628633.
>OP[TVYL>-1Y/PSHYPZ).YHIZ[HSK/9L[YVW\IPJPTWSHU[H[PVU[VPVKPULPU[OL
treatment of prostatic cancer. J Urol 1972;108:918-920.
/PSHYPZ):>OP[TVYL>-)H[H[H4, et al. Behavioral patterns of prostate adenocarcinoma
MVSSV^PUN HU 0 PTWSHU[ HUK WLS]PJ UVKL KPZZLJ[PVU Int J Radiat Oncol Biol Phys
1977;2:631-637.
ALSLMZR` 41 >OP[TVYL >- 1Y 3VUN[LYT YLZ\S[Z VM YL[YVW\IPJ WLYTHULU[ PVKPUL
implantation of the prostate for clinically localized prostatic cancer. J Urol 1997;158:2329; discussion 29-30.
Holm HH. The history of interstitial brachytherapy of prostatic cancer. Semin Surg Oncol
1997;13:431-437.
Fornage BD, Touche DH, Deglaire M, et al. Real-time ultrasound-guided prostatic
IPVWZ`\ZPUNHUL^[YHUZYLJ[HSSPULHYHYYH`WYVILRadiology 1983;146:547-548.
76:;:*907;<4
86.
76:;:*907;<4
Modelos clínico-dosimetricos en braquiterapia prostática
108.
111.
112.
115.
118.
119.
Holm HH, Juul N, Pedersen JF, et al. Transperineal 125iodine seed implantation in
prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130:283-286.
)SHZRV1*9HNKL/3\ZL9>, et al. Should brachytherapy be considered a therapeutic
option in localized prostate cancer? Urol Clin North Am 1996;23:633-650.
9HNKL/2VYI31,SNHTHS((, et al.4VKLYUWYVZ[H[LIYHJO`[OLYHW`7YVZ[H[LZWLJPÄJ
HU[PNLU YLZ\S[Z PU WH[PLU[Z ^P[O \W [V `LHYZ VM VIZLY]LK MVSSV^\W Cancer
2000;89:135-141.
Mettlin CJ, Murphy GP, McDonald CJ, et al. The National Cancer Data base Report on
PUJYLHZLK\ZLVMIYHJO`[OLYHW`MVY[OL[YLH[TLU[VMWH[PLU[Z^P[OWYVZ[H[LJHYJPUVTHPU
the U.S. Cancer 1999;86:1877-1882.
Brandeis J, Pashos CL, Henning JM, et al. ( UH[PVU^PKL JOHYNL JVTWHYPZVU VM [OL
principal treatments for early stage prostate carcinoma. Cancer 2000;89:1792-1799.
3LL>94V\NOHU16^LU1), et al. The 1999 patterns of care study of radiotherapy
in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in
the United States. Cancer 2003;98:1987-1994.
)PJL >: 7YLZ[PKNL )9 ( YL]PL^ VM WVZ[PTWSHU[ X\HSP[` HZZLZZTLU[ PU WLYTHULU[
transperineal interstitial prostate brachytherapy. J Brachyther Int 1997;13:297-313.
Prestidge BR, Prete JJ, Buchholz TA, et al. A survey of current clinical practice of
permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys
1998;40:461-465.
7YL[L117YLZ[PKNL)9)PJL>:, et al. A survey of physics and dosimetry practice of
permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys
1998;40:1001-1005.
5HN : )HPYK 4 )SHZRV 1, et al. American Brachytherapy Society (ABS) survey of
current clinical practice for permanent brachytherapy of prostate cancer. J Brachyther
Int 1997;13:243-251.
Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS)
recommendations for transperineal permanent brachytherapy of prostate cancer. Int J
Radiat Oncol Biol Phys 1999;44:789-799.
Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommendations on permanent
seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-321.
)HZ[HJR` :0 >HSZO 7* ,WZ[LPU 10 9LSH[PVUZOPW IL[^LLU WLYPUL\YHS [\TVY PU]HZPVU
on needle biopsy and radical prostatectomy capsular penetration in clinical stage B
adenocarcinoma of the prostate. Am J Surg Pathol 1993;17:336-341.
4LYYPJR.:)\[SLY>4>HSSULY2,, et al.7YVNUVZ[PJZPNUPÄJHUJLVMWLYPUL\YHSPU]HZPVU
on biochemical progression-free survival after prostate brachytherapy. Urology
2005;66:1048-1053.
+»(TPJV (= :JO\S[a + :PS]LY ), et al. The clinical utility of the percent of positive
WYVZ[H[LIPVWZPLZPUWYLKPJ[PUNIPVJOLTPJHSV\[JVTLMVSSV^PUNL_[LYUHSILHTYHKPH[PVU
[OLYHW`MVYWH[PLU[Z^P[OJSPUPJHSS`SVJHSPaLKWYVZ[H[LJHUJLYInt J Radiat Oncol Biol Phys
2001;49:679-684.
+»(TPJV (= >OP[[PUN[VU 9 4HSRV^PJa :), et al. Clinical utility of the percentage of
WVZP[P]LWYVZ[H[LIPVWZPLZPUKLÄUPUNIPVJOLTPJHSV\[JVTLHM[LYYHKPJHSWYVZ[H[LJ[VT`
MVYWH[PLU[Z^P[OJSPUPJHSS`SVJHSPaLKWYVZ[H[LJHUJLYJ Clin Oncol 2000;18:1164-1172.
+»(TPJV(=2LZOH]PHO(4HUVSH1, et al. Clinical utility of the percentage of positive
WYVZ[H[L IPVWZPLZ PU WYLKPJ[PUN WYVZ[H[L JHUJLYZWLJPÄJ HUK V]LYHSS Z\Y]P]HS HM[LY
YHKPV[OLYHW`MVYWH[PLU[Z^P[OSVJHSPaLKWYVZ[H[LJHUJLYInt J Radiat Oncol Biol Phys
2002;53:581-587.
4LYYPJR.:)\[SLY>4>HSSULY2,, et al.7YVNUVZ[PJZPNUPÄJHUJLVMWLYJLU[WVZP[P]L
IPVWZPLZPUJSPUPJHSS`VYNHUJVUÄULKWYVZ[H[LJHUJLY[YLH[LK^P[OWLYTHULU[WYVZ[H[L
IYHJO`[OLYHW` ^P[O VY ^P[OV\[ Z\WWSLTLU[HS L_[LYUHSILHT YHKPH[PVU Cancer J
2004;10:54-60.
9VZZP71*SHYR7,7HWHNPRVZ4(, et al. Percentage of positive biopsies associated
^P[OMYLLKVTMYVTIPVJOLTPJHSYLJ\YYLUJLHM[LYSV^KVZLYH[LWYVZ[H[LIYHJO`[OLYHW`
alone for clinically localized prostate cancer. Urology 2006;67:349-353.
4HY[LUZ*7VUK.>LIZ[LY+, et al. Relationship of the International Prostate Symptom
POSTSCRIPTUM
143.
146.
76:;:*907;<4
ZJVYL ^P[O \YPUHY` ÅV^ Z[\KPLZ HUK JH[OL[LYPaH[PVU YH[LZ MVSSV^PUN 0 WYVZ[H[L
brachytherapy. Brachytherapy 2006;5:9-13.
/LUKLYZVU(*HOPSS+3HPUN9>, et al. (125)Iodine prostate brachytherapy: outcome from
[OLÄYZ[JVUZLJ\[P]LWH[PLU[ZHUKZLSLJ[PVUZ[YH[LNPLZPUJVYWVYH[PUN\YVK`UHTPJZ
BJU Int 2002;90:567-572.
:OLYLY[a ; >HSSULY 2 >HUN /, et al. Long-term urinary function after transperineal
IYHJO`[OLYHW` MVY WH[PLU[Z ^P[O SHYNL WYVZ[H[L NSHUKZ Int J Radiat Oncol Biol Phys
2001;51:1241-1245.
4LYYPJR.:)\[SLY>43PLM1/, et al.;LTWVYHSYLZVS\[PVUVM\YPUHY`TVYIPKP[`MVSSV^PUN
prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:121-128.
4LYYPJR.:)\[SLY>4>HSSULY2,, et al. Long-term urinary quality of life after permanent
prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56:454-461.
4LYYPJR.:)\[SLY>4>HSSULY2,, et al. The impact of prostate volume and neoadjuvant
HUKYVNLUKLWYP]H[PVU [OLYHW` VU \YPUHY` M\UJ[PVU MVSSV^PUN WYVZ[H[L IYHJO`[OLYHW`
Cancer J 2004;10:181-189.
5PLOH\Z ( 4LYYPJR .: )\[SLY >4, et al. ;OL PUÅ\LUJL VM PZV[VWL HUK WYVZ[H[L
volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys
2006;64:136-143.
:[VUL55:[VJR9.7YVZ[H[LIYHJO`[OLYHW`PUWH[PLU[Z^P[OWYVZ[H[L]VS\TLZ%$
cm(3): dosimetic analysis of implant quality. Int J Radiat Oncol Biol Phys 2000;46:11991204.
.YPTT7+)SHZRV1*9HNKL/, et al. Does brachytherapy have a role in the treatment
of prostate cancer? Hematol Oncol Clin North Am 1996;10:653-673.
>HSSULY 2 3LL / >HZZLYTHU :, et al. 3V^ YPZR VM \YPUHY` PUJVU[PULUJL MVSSV^PUN
WYVZ[H[L IYHJO`[OLYHW` PU WH[PLU[Z ^P[O H WYPVY [YHUZ\YL[OYHS WYVZ[H[L YLZLJ[PVU Int J
Radiat Oncol Biol Phys 1997;37:565-569.
*LZHYL[[P 1( :[VUL 55 :[VJR 9. +VLZ WYPVY [YHUZ\YL[OYHS YLZLJ[PVU VM WYVZ[H[L
compromise brachytherapy quality: a dosimetric analysis. Int J Radiat Oncol Biol Phys
2004;60:648-653.
*VYTHJR 9( ;LTWHU` *4 +»(TPJV (= 6W[PTPaPUN [HYNL[ JV]LYHNL I` KVZPTL[YPJ
MLLKIHJRK\YPUNWYVZ[H[LIYHJO`[OLYHW`Int J Radiat Oncol Biol Phys 2000;48:12451249.
>PSRPUZVU +( 3LL ,1 *PLaRP 17, et al. Dosimetric comparison of pre-planned and
or-planned prostate seed brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:12411244.
5HN : )PJL > +L>`UNHLY[ 2, et al. The American Brachytherapy Society
recommendations for permanent prostate brachytherapy postimplant dosimetric
analysis. Int J Radiat Oncol Biol Phys 2000;46:221-230.
.L^HU[LY 94 >\\ * 3HN\UH 13, et al. Intraoperative preplanning for transperineal
ultrasound-guided permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys
2000;48:377-380.
ALSLMZR` 41 @HTHKH @ *VOLU ., et al. Postimplantation dosimetric analysis of
WLYTHULU[ [YHUZWLYPULHS WYVZ[H[L PTWSHU[H[PVU! PTWYV]LK KVZL KPZ[YPI\[PVUZ ^P[O HU
intraoperative computer-optimized conformal planning technique. Int J Radiat Oncol
Biol Phys 2000;48:601-608.
Yu Y, Zhang JB, Brasacchio RA, et al. Automated treatment planning engine for prostate
seed implant brachytherapy. Int J Radiat Oncol Biol Phys 1999;43:647-652.
AHPKLY4ALSLMZR`413LL,2, et al. Treatment planning for prostate implants using
magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2000;47:10851096.
+»(TPJV (= *VYTHJR 9 ;LTWHU` *4, et al. Real-time magnetic resonance imageN\PKLK PU[LYZ[P[PHS IYHJO`[OLYHW` PU [OL [YLH[TLU[ VM ZLSLJ[ WH[PLU[Z ^P[O JSPUPJHSS`
localized prostate cancer. Int J Radiat Oncol Biol Phys 1998;42:507-515.
Messing EM, Zhang JB, Rubens DJ, et al. Intraoperative optimized inverse planning for
prostate brachytherapy: early experience. Int J Radiat Oncol Biol Phys 1999;44:801808.
76:;:*907;<4
Modelos clínico-dosimetricos en braquiterapia prostática
147.
148.
158.
162.
164.
Stone NN, Hong S, Lo YC, et al. Comparison of intraoperative dosimetric implant
YLWYLZLU[H[PVU^P[OWVZ[PTWSHU[KVZPTL[Y`PUWH[PLU[ZYLJLP]PUNWYVZ[H[LIYHJO`[OLYHW`
Brachytherapy 2003;2:17-25.
Ragde H, Grado GL, Nadir B, et al. Modern prostate brachytherapy. CA Cancer J Clin
2000;50:380-393.
:[VJR9.:[VUL55;OLLMMLJ[VMWYVNUVZ[PJMHJ[VYZVU[OLYHWL\[PJV\[JVTLMVSSV^PUN
transperineal prostate brachytherapy. Semin Surg Oncol 1997;13:454-460.
+»(TPJV (= >OP[[PUN[VU 9 4HSRV^PJa :), et al. Biochemical outcome after radical
prostatectomy, external beam radiation therapy, or interstitial radiation therapy for
clinically localized prostate cancer. Jama 1998;280:969-974.
9HNKL/,SNHTHS((:UV^7), et al. Ten-year disease free survival after transperineal
ZVUVNYHWO`N\PKLKPVKPULIYHJO`[OLYHW`^P[OVY^P[OV\[NYH`L_[LYUHSILHT
PYYHKPH[PVU PU [OL [YLH[TLU[ VM WH[PLU[Z ^P[O JSPUPJHSS` SVJHSPaLK SV^ [V OPNO .SLHZVU
grade prostate carcinoma. Cancer 1998;83:989-1001.
)SHZRV1*.YPTT7+:`SZ]LZ[LY1,, et al.;OLYVSLVML_[LYUHSILHTYHKPV[OLYHW`^P[O
I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57:273278.
*H]HUHNO>)SHZRV1*.YPTT7+, et al.;YHUZPLU[LSL]H[PVUVMZLY\TWYVZ[H[LZWLJPÄJ
HU[PNLUMVSSV^PUN07KIYHJO`[OLYHW`MVYSVJHSPaLKWYVZ[H[LJHUJLYSemin Urol
Oncol 2000;18:160-165.
2VSSTLPLY4(:[VJR9.:[VUL5)PVJOLTPJHSV\[JVTLZHM[LYWYVZ[H[LIYHJO`[OLYHW`
^P[O`LHYTPUPTHSMVSSV^\W!PTWVY[HUJLVMWH[PLU[ZLSLJ[PVUHUKPTWSHU[X\HSP[`Int J
Radiat Oncol Biol Phys 2003;57:645-653.
ALSLMZR` 41 /VSSPZ[LY ; 9HILU (, et al. Five-year biochemical outcome and toxicity
^P[O[YHUZWLYPULHS*;WSHUULKWLYTHULU[0WYVZ[H[LPTWSHU[H[PVUMVYWH[PLU[Z^P[O
localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;47:1261-1266.
:OHYRL`1*OV]UPJR:+)LOHY91, et al. Outpatient ultrasound-guided palladium 103
brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434
patients. Urology 1998;51:796-803.
2H`L2>6SZVU+17H`UL1;+L[HPSLKWYLSPTPUHY`HUHS`ZPZVMPVKPULPTWSHU[H[PVU
for localized prostate cancer using percutaneous approach. J Urol 1995;153:10201025.
Battermann JJ. I-125 implantation for localized prostate cancer: the Utrecht University
experience. Radiother Oncol 2000;57:269-272.
)L`LY +* 7YPLZ[SL` 1) 1Y )PVJOLTPJHS KPZLHZLMYLL Z\Y]P]HS MVSSV^PUN 0 WYVZ[H[L
implantation. Int J Radiat Oncol Biol Phys 1997;37:559-563.
>HSSULY29V`1/HYYPZVU3;\TVYJVU[YVSHUKTVYIPKP[`MVSSV^PUN[YHUZWLYPULHSPVKPUL
125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-453.
)SHZRV1*>HSSULY2.YPTT7+, et al.7YVZ[H[LZWLJPÄJHU[PNLUIHZLKKPZLHZLJVU[YVS
MVSSV^PUN\S[YHZV\UKN\PKLKPVKPULPTWSHU[H[PVUMVYZ[HNL;;WYVZ[H[PJJHYJPUVTH
J Urol 1995;154:1096-1099.
Grado GL, Larson TR, Balch CS, et al. Actuarial disease-free survival after prostate
JHUJLY IYHJO`[OLYHW` \ZPUN PU[LYHJ[P]L [LJOUPX\LZ ^P[O IPWSHUL \S[YHZV\UK HUK
Å\VYVZJVWPJN\PKHUJLInt J Radiat Oncol Biol Phys 1998;42:289-298.
4LYYPJR .: )\[SLY >4 3PLM 1/, et al. Five-year biochemical outcome after prostate
brachytherapy for hormone-naive men < or = 62 years of age. Int J Radiat Oncol Biol
Phys 2001;50:1253-1257.
Storey MR, Landgren RC, Cottone JL, et al. Transperineal 125iodine implantation for
treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. Int
J Radiat Oncol Biol Phys 1999;43:565-570.
)SHUR3,.VUaHSLa.VUaHSLa+KL9LPQRL;4, et al.)YHJO`[OLYHW`^P[O[YHUZWLYPULHS
(125)Iodine seeds for localized prostate cancer. Radiother Oncol 2000;57:307-313.
ALSLMZR`412\IHU+(3L]`3), et al. Multi-institutional analysis of long-term outcome
MVYZ[HNLZ;;WYVZ[H[LJHUJLY[YLH[LK^P[OWLYTHULU[ZLLKPTWSHU[H[PVUInt J Radiat
Oncol Biol Phys 2007;67:327-333.
)SHZRV 1* .YPTT 7+ :`S]LZ[LY 1,, et al. Palladium-103 brachytherapy for prostate
POSTSCRIPTUM
169.
175.
176.
178.
carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-850.
.YPTT 7+ )SHZRV 1* :`S]LZ[LY 1,, et al. `LHY IPVJOLTPJHS WYVZ[H[LZWLJPÄJ
HU[PNLUJVU[YVSVMWYVZ[H[LJHUJLY^P[O0IYHJO`[OLYHW`Int J Radiat Oncol Biol
Phys 2001;51:31-40.
Ragde H, Grado GL, Nadir BS. Brachytherapy for clinically localized prostate cancer:
thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated
^P[OWLYTHULU[PTWSHU[ZHSVULArch Esp Urol 2001;54:739-747.
:PUNO(ALSLMZR`419HILU(, et al. Combined 3-dimensional conformal radiotherapy
HUK [YHUZWLYPULHS 7K WLYTHULU[ PTWSHU[H[PVU MVY WH[PLU[Z ^P[O PU[LYTLKPH[L HUK
\UMH]VYHISLYPZRWYVZ[H[LJHUJLYInt J Cancer 2000;90:275-280.
+H[[VSP4>HSSULY2:VYHJL9, et al. 103Pd brachytherapy and external beam irradiation
MVY JSPUPJHSS` SVJHSPaLK OPNOYPZR WYVZ[H[PJ JHYJPUVTH Int J Radiat Oncol Biol Phys
1996;35:875-879.
3LKLYTHU.:*H]HUHNO>(SILY[7:, et al.9L[YVZWLJ[P]LZ[YH[PÄJH[PVUVMHJVUZLJ\[P]L
JVOVY[VMWYVZ[H[LJHUJLYWH[PLU[Z[YLH[LK^P[OHJVTIPULKYLNPTLUVML_[LYUHSILHT
radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 2001;49:1297-1303.
:`S]LZ[LY1,.YPTT7+)SHZRV1*, et al. 15-Year biochemical relapse free survival in
JSPUPJHS:[HNL;;WYVZ[H[LJHUJLYMVSSV^PUNJVTIPULKL_[LYUHSILHTYHKPV[OLYHW`
and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007;67:57-64.
;HSJV[[ 1( *SHYR 1( :[HYR 7*, et al. Long-term treatment related complications of
brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol
2001;166:494-499.
Nag S, Scaperoth DD, Badalament R, et al. Transperineal palladium 103 prostate
brachytherapy: analysis of morbidity and seed migration. Urology 1995;45:87-92.
Gelblum DY, Potters L, Ashley R, et al.<YPUHY`TVYIPKP[`MVSSV^PUN\S[YHZV\UKN\PKLK
transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45:59-67.
)LUVP[945HZS\UK41*VOLU12*VTWSPJH[PVUZHM[LYWYVZ[H[LIYHJO`[OLYHW`PU[OL
Medicare population. Urology 2000;55:91-96.
Zeitlin SI, Sherman J, Raboy A, et al. High dose combination radiotherapy for the
treatment of localized prostate cancer. J Urol 1998;160:91-95; discussion 95-96.
:[VUL55:[VJR9.7YVZ[H[LIYHJO`[OLYHW`![YLH[TLU[Z[YH[LNPLZJ Urol 1999;162:421426.
9HNKL / 2VYI 3 )YHJO`[OLYHW` MVY JSPUPJHSS` SVJHSPaLK WYVZ[H[L JHUJLY Semin Surg
Oncol 2000;18:45-51.
;LYR4+:[VJR9.:[VUL550KLU[PÄJH[PVUVMWH[PLU[ZH[PUJYLHZLKYPZRMVYWYVSVUNLK
\YPUHY` YL[LU[PVU MVSSV^PUN YHKPVHJ[P]L ZLLK PTWSHU[H[PVU VM [OL WYVZ[H[L J Urol
1998;160:1379-1382.
4J,S]LLU;3>H[LYTHU-42PT/, et al. Factors predicting for urinary incontinence
after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004;59:1395-1404.
)\JJP 1 4VYYPZ >1 2L`LZ 4, et al. 7YLKPJ[P]L MHJ[VYZ VM \YPUHY` YL[LU[PVU MVSSV^PUN
prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;53:91-98.
>HSSULY 2 9V` 1 /HYYPZVU 3 +VZPTL[Y` N\PKLSPULZ [V TPUPTPaL \YL[OYHS HUK YLJ[HS
TVYIPKP[`MVSSV^PUN[YHUZWLYPULHS0WYVZ[H[LIYHJO`[OLYHW`Int J Radiat Oncol Biol
Phys 1995;32:465-471.
+LZHP1:[VJR9.:[VUL55, et al.(J\[L\YPUHY`TVYIPKP[`MVSSV^PUN0PU[LYZ[P[PHS
implantation of the prostate gland. Radiat Oncol Investig 1998;6:135-141.
2L`LZ4:JOLSSLUILYN+4VYH]HU=, et al. Decline in urinary retention incidence in 805
patients after prostate brachytherapy: the effect of learning curve? Int J Radiat Oncol
Biol Phys 2006;64:825-834.
=PQ]LYILYN 73 2\Y[O 2/ )SHUR 3,, et al. Treatment of localized prostatic carcinoma
using the transrectal ultrasound guided transperineal implantation technique. Eur Urol
1992;21:35-41.
)SHZRV1*9HNKL/.YPTT7+;YHUZWLYPULHS\S[YHZV\UKN\PKLKPTWSHU[H[PVUVM[OL
prostate: morbidity and complications. Scand J Urol Nephrol Suppl 1991;137:113118.
3LL5>\\*:)YVK`9, et al. Factors predicting for postimplantation urinary retention
76:;:*907;<4
76:;:*907;<4
Modelos clínico-dosimetricos en braquiterapia prostática
198.
after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:14571460.
;OVTHZ4+*VYTHJR9;LTWHU`*4, et al. Identifying the predictors of acute urinary
YL[LU[PVU MVSSV^PUN THNUL[PJYLZVUHUJLN\PKLK WYVZ[H[L IYHJO`[OLYHW` Int J Radiat
Oncol Biol Phys 2000;47:905-908.
4LYYPJR.:)\[SLY>4+VYZL`(;, et al.0UÅ\LUJLVMWYVWO`SHJ[PJKL_HTL[OHZVULVU
LKLTHMVSSV^PUNWYVZ[H[LIYHJO`[OLYHW`Tech Urol 2000;6:117-122.
:WLPNO[13:OPUVOHYH27PJRL[[), et al. Prostate volume change after radioactive seed
PTWSHU[H[PVU!WVZZPISLILULÄ[VMPTWYV]LKKVZL]VS\TLOPZ[VNYHT^P[OWLYPVWLYH[P]L
steroid. Int J Radiat Oncol Biol Phys 2000;48:1461-1467.
9HNKL/)SHZRV1*.YPTT7+, et al.0U[LYZ[P[PHSPVKPULYHKPH[PVU^P[OV\[HKQ\]HU[
therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442453.
ALSLMZR` 41 >HSSULY 2, 3PUN **, et al. Comparison of the 5-year outcome and
morbidity of three-dimensional conformal radiotherapy versus transperineal permanent
iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999;17:517522.
4LYYPJR.:)\[SLY>4;VSSLUHHY)., et al. The dosimetry of prostate brachytherapyinduced urethral strictures. Int J Radiat Oncol Biol Phys 2002;52:461-468.
:[VJR 9. :[VUL 55 +L>`UNHLY[ 12, et al. 7YVZ[H[L ZWLJPÄJ HU[PNLU ÄUKPUNZ HUK
IPVWZ`YLZ\S[ZMVSSV^PUNPU[LYHJ[P]L\S[YHZV\UKN\PKLK[YHUZWLYPULHSIYHJO`[OLYHW`MVY
early stage prostate carcinoma. Cancer 1996;77:2386-2392.
2SLPUILYN 3 >HSSULY 2 9V` 1, et al. ;YLH[TLU[YLSH[LK Z`TW[VTZ K\YPUN [OL ÄYZ[
`LHY MVSSV^PUN [YHUZWLYPULHS 0 WYVZ[H[L PTWSHU[H[PVU Int J Radiat Oncol Biol Phys
1994;28:985-990.
Lepor H, Gregerman M, Crosby R, et al. Precise localization of the autonomic nerves
from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the
adult male pelvis. J Urol 1985;133:207-212.
4LYYPJR .: )\[SLY >4 +VYZL` (;, et al. A comparison of radiation dose to the
UL\YV]HZJ\SHYI\UKSLZPUTLU^P[OHUK^P[OV\[WYVZ[H[LIYHJO`[OLYHW`PUK\JLKLYLJ[PSL
dysfunction. Int J Radiat Oncol Biol Phys 2000;48:1069-1074.
4LYYPJR.:>HSSULY2)\[SLY>4, et al. A comparison of radiation dose to the bulb of
[OLWLUPZPUTLU^P[OHUK^P[OV\[WYVZ[H[LIYHJO`[OLYHW`PUK\JLKLYLJ[PSLK`ZM\UJ[PVU
Int J Radiat Oncol Biol Phys 2001;50:597-604.
-PZJO)47PJRL[[)>LPUILYN=, et al. Dose of radiation received by the bulb of the
WLUPZJVYYLSH[LZ^P[OYPZRVMPTWV[LUJLHM[LY[OYLLKPTLUZPVUHSJVUMVYTHSYHKPV[OLYHW`
for prostate cancer. Urology 2001;57:955-959.
3P[^PU 4: 3\ILJR +7 /LUUPUN 14, et al. Differences in urologist and patient
HZZLZZTLU[ZVMOLHS[OYLSH[LKX\HSP[`VMSPMLPUTLU^P[OWYVZ[H[LJHUJLY!YLZ\S[ZVM[OL
CaPSURE database. J Urol 1998;159:1988-1992.
4LYYPJR.:)\[SLY>4.HSIYLH[O9>, et al. Erectile function after permanent prostate
brachytherapy. Int J Radiat Oncol Biol Phys 2002;52:893-902.
:[VJR9.2HV1:[VUL557LUPSLLYLJ[PSLM\UJ[PVUHM[LYWLYTHULU[YHKPVHJ[P]LZLLK
implantation for treatment of prostate cancer. J Urol 2001;165:436-439.
ALSLMZR`414J2LL()3LL/, et al.,MÄJHJ`VMVYHSZPSKLUHÄSPUWH[PLU[Z^P[OLYLJ[PSL
dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999;53:775778.
/HURZ ., :JO\S[OLPZZ ;, /HUSVU (3, et al. Optimization of conformal radiation
treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol
Phys 1997;37:543-550.
ALSLMZR` 41 *V^LU + -\RZ A, et al. Long term tolerance of high dose threeKPTLUZPVUHS JVUMVYTHS YHKPV[OLYHW` PU WH[PLU[Z ^P[O SVJHSPaLK WYVZ[H[L JHYJPUVTH
Cancer 1999;85:2460-2468.
:R^HYJO\R 4> 1HJRZVU ( ALSLMZR` 41, et al. Late rectal toxicity after conformal
radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat
Oncol Biol Phys 2000;47:103-113.
POSTSCRIPTUM
214.
215.
216.
223.
224.
227.
228.
)VLYZTH 31 ]HU KLU )YPUR 4 )Y\JL (4, et al. Estimation of the incidence of late
bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy
for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys
1998;41:83-92.
/HY[MVYK (* 5PLTPLYRV ( (KHTZ 1(, et al. Conformal irradiation of the prostate:
LZ[PTH[PUNSVUN[LYTYLJ[HSISLLKPUNYPZR\ZPUNKVZL]VS\TLOPZ[VNYHTZInt J Radiat
Oncol Biol Phys 1996;36:721-730.
4LYYPJR.:)\[SLY>4+VYZL`(;, et al.9LJ[HSKVZPTL[YPJHUHS`ZPZMVSSV^PUNWYVZ[H[L
brachytherapy. Int J Radiat Oncol Biol Phys 1999;43:1021-1027.
:U`KLY24:[VJR9./VUN:4, et al.+LÄUPUN[OLYPZRVMKL]LSVWPUNNYHKLWYVJ[P[PZ
MVSSV^PUN0WYVZ[H[LIYHJO`[OLYHW`\ZPUNHYLJ[HSKVZL]VS\TLOPZ[VNYHTHUHS`ZPZ
Int J Radiat Oncol Biol Phys 2001;50:335-341.
/PSHYPZ ): >OP[TVYL >- 1Y )H[H[H 4(, et al. Radiation therapy and pelvic node
dissection in the management of cancer of the prostate. Am J Roentgenol Radium Ther
Nucl Med 1974;121:832-838.
Anderson LL. Spacing nomograph for interstitial implants of 125I seeds. Med Phys
1976;3:48-51.
Yu Y, Anderson LL, Li Z, et al. Permanent prostate seed implant brachytherapy: report
VM[OL(TLYPJHU(ZZVJPH[PVUVM7O`ZPJPZ[ZPU4LKPJPUL;HZR.YV\W5VMed Phys
1999;26:2054-2076.
Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources:
YLJVTTLUKH[PVUZ VM [OL ((74 9HKPH[PVU ;OLYHW` *VTTP[[LL ;HZR .YV\W 5V American Association of Physicists in Medicine. Med Phys 1995;22:209-234.
2\IV/+*V\YZL`)4/HUZVU>-, et al. Report of the ad hoc committee of the AAPM
radiation therapy committee on 125I sealed source dosimetry. Int J Radiat Oncol Biol
Phys 1998;40:697-702.
3PUN**@VYRL,+:WPYV01, et al.7O`ZPJHSKVZPTL[Y`VM0ZLLKZVMHUL^KLZPNUMVY
interstitial implant. Int J Radiat Oncol Biol Phys 1983;9:1747-1752.
9V`15>HSSULY2,/HYYPUN[VU71, et al. A CT-based evaluation method for permanent
implants: application to prostate. Int J Radiat Oncol Biol Phys 1993;26:163-169.
>PSSPUZ1>HSSULY2*;IHZLKKVZPTL[Y`MVY[YHUZWLYPULHS0WYVZ[H[LIYHJO`[OLYHW`
Int J Radiat Oncol Biol Phys 1997;39:347-353.
@\ @ >H[LYTHU -4 :\U[OHYHSPUNHT 5, et al. Limitations of the minimum peripheral
KVZLHZHWHYHTL[LYMVYKVZLZWLJPÄJH[PVUPUWLYTHULU[0WYVZ[H[LPTWSHU[ZInt J
Radiat Oncol Biol Phys 1996;34:717-725.
7V[[LYZ3*HSN\HY\,;OVYU[VU2), et al.;V^HYKHK`UHTPJYLHS[PTLPU[YHVWLYH[P]L
permanent prostate brachytherapy methodology. Brachytherapy 2003;2:172-180.
Potters L, Calugaru E, Jassal A, et al. Is there a role for postimplant dosimetry after
real-time dynamic permanent prostate brachytherapy? Int J Radiat Oncol Biol Phys
2006;65:1014-1019.
Acher P, Popert R, Nichol J, et al. Permanent prostate brachytherapy: Dosimetric results
HUKHUHS`ZPZVMHSLHYUPUNJ\Y]L^P[OHK`UHTPJKVZLMLLKIHJR[LJOUPX\LInt J Radiat
Oncol Biol Phys 2006;65:694-698.
ALSLMZR`41AHPKLY43V^KVZLYH[LIYHJO`[OLYHW`MVYWYVZ[H[LJHUJLY!WYLWSHUUPUN
vs. intraoperative planning-intraoperative planning is best. Brachytherapy 2006;5:143144; discussion 146.
AHPKLY4ALSLMZR`41*VOLU.5, et al. Methodology for biologically-based treatment
WSHUUPUN MVY JVTIPULK SV^KVZLYH[L WLYTHULU[ PTWSHU[ HUK OPNOKVZLYH[L
(fractionated) treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2005;61:702713.
Todor DA, Zaider M, Cohen GN, et al. Intraoperative dynamic dosimetry for prostate
implants. Phys Med Biol 2003;48:1153-1171.
Anderson LL. A “natural” volume-dose histogram for brachytherapy. Med Phys
1986;13:898-903.
]HU»[ 9PL[ ( [L 3VV /1 @WTH (-, et al. Ultrasonically guided transperineal seed
PTWSHU[H[PVUVM[OLWYVZ[H[L!TVKPÄJH[PVUVM[OL[LJOUPX\LHUKX\HSP[H[P]LHZZLZZTLU[
76:;:*907;<4
76:;:*907;<4
Modelos clínico-dosimetricos en braquiterapia prostática
231.
238.
242.
246.
248.
249.
of implants. Int J Radiat Oncol Biol Phys 1992;24:555-558.
@\@(UVUKP]LYNLU[ZWLJPÄJH[PVUVM[OLTLHU[YLH[TLU[KVZLPUPU[LYZ[P[PHSIYHJO`[OLYHW`
Med Phys 1996;23:905-909.
Nath R, Meigooni AS, Melillo A. Some treatment planning considerations for 103Pd and
125I permanent interstitial implants. Int J Radiat Oncol Biol Phys 1992;22:1131-1138.
5H[O99VILY[Z25N4, et al. Correlation of medical dosimetry quality indicators to the
SVJHS[\TVYJVU[YVSPUWH[PLU[Z^P[OWYVZ[H[LJHUJLY[YLH[LK^P[OPVKPULPU[LYZ[P[PHS
implants. Med Phys 1998;25:2293-2307.
:H^*):\U[OHYHSPUNHT58\HU[P[H[P]LHZZLZZTLU[VMPU[LYZ[P[PHSPTWSHU[ZInt J Radiat
Oncol Biol Phys 1991;20:135-139.
+\IVPZ+-7YLZ[PKNL)9/V[JORPZZ3(, et al. Intraobserver and interobserver variability
of MR imaging- and CT-derived prostate volumes after transperineal interstitial
permanent prostate brachytherapy. Radiology 1998;207:785-789.
+\IVPZ+-7YLZ[PKNL)9/V[JORPZZ3(, et al.:V\YJLSVJHSPaH[PVUMVSSV^PUNWLYTHULU[
transperineal prostate interstitial brachytherapy using magnetic resonance imaging. Int
J Radiat Oncol Biol Phys 1997;39:1037-1041.
4VLYSHUK4(>PQYKLTHU/2)LLYZTH9, et al. Evaluation of permanent I-125 prostate
implants using radiography and magnetic resonance imaging. Int J Radiat Oncol Biol
Phys 1997;37:927-933.
?\L1>H[LYTHU-/HUKSLY1, et al.3VJHSPaH[PVUVMSPURLK0ZLLKZPUWVZ[PTWSHU[
TRUS images for prostate brachytherapy dosimetry. Int J Radiat Oncol Biol Phys
2005;62:912-919.
Narayana V, Roberson PL, Pu AT, et al. Impact of differences in ultrasound and
computed tomography volumes on treatment planning of permanent prostate implants.
Int J Radiat Oncol Biol Phys 1997;37:1181-1185.
5HYH`HUH = 9VILYZVU 73 >PUÄLSK 91, et al. Impact of ultrasound and computed
tomography prostate volume registration on evaluation of permanent prostate implants.
Int J Radiat Oncol Biol Phys 1997;39:341-346.
+\IVPZ +- )PJL >: 1Y 7YLZ[PNL )9 *; HUK 490 KLYP]LK ZV\YJL SVJHSPaH[PVU LYYVY
in a custom prostate phantom using automated image coregistration. Med Phys
2001;28:2280-2284.
(TK\Y91.SHKZ[VUL+3LVWVSK2(, et al. Prostate seed implant quality assessment
using MR and CT image fusion. Int J Radiat Oncol Biol Phys 1999;43:67-72.
Polo A, Cattani F, Vavassori A, et al. MR and CT image fusion for postimplant analysis in
permanent prostate seed implants. Int J Radiat Oncol Biol Phys 2004;60:1572-1579.
)HKPVaHTHUP29>HSSULY2*H]HUHNO>, et al. Comparability of CT-based and TRUSbased prostate volumes. Int J Radiat Oncol Biol Phys 1999;43:375-378.
9VHJO 4 YK -HPSSHJL(RHaH^H 7 4HSMH[[P *, et al. 7YVZ[H[L ]VS\TLZ KLÄULK I`
magnetic resonance imaging and computerized tomographic scans for threedimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996;35:1011-1018.
9VZLU002OHU243HUL9., et al. The effect of geometric errors in the reconstruction
of iridium-192 seed implants. Med Phys 1982;9:220-223.
Al-Qaisieh B, Ash D, Bottomley DM, et al. Impact of prostate volume evaluation by
different observers on CT-based post-implant dosimetry. Radiother Oncol 2002;62:267273.
3LL>99VHJO4YK4PJOHSZRP1, et al.0U[LYVIZLY]LY]HYPHIPSP[`SLHKZ[VZPNUPÄJHU[
KPMMLYLUJLZ PU X\HU[PÄLYZ VM WYVZ[H[L PTWSHU[ HKLX\HJ` Int J Radiat Oncol Biol Phys
2002;54:457-461.
Cazzaniga LF, Marinoni MA, Bossi A, et al. 0U[LYWO`ZPJPHU ]HYPHIPSP[` PU KLÄUPUN [OL
planning target volume in the irradiation of prostate and seminal vesicles. Radiother
Oncol 1998;47:293-296.
Fiorino C, Reni M, Bolognesi A, et al. Intra- and inter-observer variability in contouring
prostate and seminal vesicles: implications for conformal treatment planning. Radiother
Oncol 1998;47:285-292.
=HSPJLU[P92:^LL[1>/H\JR>>, et al.=HYPH[PVUVMJSPUPJHS[HYNL[]VS\TLKLÄUP[PVU
in three-dimensional conformal radiation therapy for prostate cancer. Int J Radiat Oncol
POSTSCRIPTUM
253.
258.
268.
Biol Phys 1999;44:931-935.
:HUKSLY /4 )YLL 93 4J3H\NOSPU 7>, et al. Localization of the prostatic apex for
YHKPH[PVU[OLYHW`\ZPUNPTWSHU[LKTHYRLYZInt J Radiat Oncol Biol Phys 1993;27:915919.
2HNH^H23LL>9:JO\S[OLPZZ;,, et al. Initial clinical assessment of CT-MRI image
M\ZPVUZVM[^HYLPUSVJHSPaH[PVUVM[OLWYVZ[H[LMVY+JVUMVYTHSYHKPH[PVU[OLYHW`Int J
Radiat Oncol Biol Phys 1997;38:319-325.
Rasch C, Barillot I, Remeijer P, et al.+LÄUP[PVUVM[OLWYVZ[H[LPU*;HUK490!HT\S[P
observer study. Int J Radiat Oncol Biol Phys 1999;43:57-66.
4LYYPJR .: )\[SLY >4 +VYZL` (;, et al. The dependence of prostate postimplant
dosimetric quality on CT volume determination. Int J Radiat Oncol Biol Phys
1999;44:1111-1117.
3LL>9KL.\aTHU(-)HYL93, et al. Postimplant analysis of transperineal interstitial
WLYTHULU[WYVZ[H[LIYHJO`[OLYHW`!L]PKLUJLMVYHSLHYUPUNJ\Y]LPU[OLÄYZ[`LHYH[H
single institution. Int J Radiat Oncol Biol Phys 2000;46:83-88.
)PJL>:1Y7YLZ[PKNL)9.YPTT7+, et al. Centralized multiinstitutional postimplant
analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;41:921927.
/YPJHR / 1LMMYL` 9) +VVTZ.*, et al. Evaluation of prostate size: a comparison of
ultrasound and magnetic resonance imaging. Urol Radiol 1987;9:1-8.
Rahmouni A, Yang A, Tempany CM, et al. Accuracy of in-vivo assessment of prostatic
volume by MRI and transrectal ultrasonography. J Comput Assist Tomogr 1992;16:935940.
HS9PTH^P 4 .YPMÄ[OZ +1 )VHRL 9*, et al. Transrectal ultrasound versus magnetic
resonance imaging in the estimation of prostatic volume. Br J Urol 1994;74:596-600.
;L^HYP ( 0UK\KOHYH 9 :OPUVOHYH 2, et al. Comparison of transrectal ultrasound
WYVZ[H[PJ]VS\TLLZ[PTH[PVU^P[OTHNUL[PJYLZVUHUJLPTHNPUN]VS\TLLZ[PTH[PVUHUK
Z\YNPJHSZWLJPTLU^LPNO[PUWH[PLU[Z^P[OILUPNUWYVZ[H[PJO`WLYWSHZPHJ Clin Ultrasound
1996;24:169-174.
;LYYPZ42:[HTL`;(+L[LYTPUH[PVUVMWYVZ[H[L]VS\TLI`[YHUZYLJ[HS\S[YHZV\UKJ
Urol 1991;145:984-987.
;LYYPZ424J5LHS1,:[HTL`;(,Z[PTH[PVUVMWYVZ[H[LJHUJLY]VS\TLI`[YHUZYLJ[HS
ultrasound imaging. J Urol 1992;147:855-857.
:VZUH19VMZR`54.HZ[VU:4, et al. Determinations of prostate volume at 3-Tesla
using an external phased array coil: comparison to pathologic specimens. Acad Radiol
2003;10:846-853.
7YL[L117YLZ[PKNL)9)PJL>:, et al. Comparison of MRI- and CT-based post-implant
dosimetric analysis of transperineal interstitial permanent prostate brachytherapy.
Radiat Oncol Investig 1998;6:90-96.
=H\WLS72HSSPUV^ZRP-6R\UPLMM7)SVVKÅV^V_`NLUHUKU\[YPLU[Z\WWS`HUKTL[HIVSPJ
TPJYVLU]PYVUTLU[VMO\THU[\TVYZ!HYL]PL^Cancer Res 1989;49:6449-6465.
)YV^U 14 .PHJJPH (1 ;OL \UPX\L WO`ZPVSVN` VM ZVSPK [\TVYZ! VWWVY[\UP[PLZ HUK
problems) for cancer therapy. Cancer Res 1998;58:1408-1416.
@HV 2: *SH`[VU 4 6»+^`LY 71 (WVW[VZPZ PU O\THU HKLUVJHYJPUVTH /; JLSSZ
induced by exposure to hypoxia. J Natl Cancer Inst 1995;87:117-122.
van den Berg AP, van Geel CA, van Hooije CM, et al. Tumor hypoxia--a confounding
or exploitable factor in interstitial brachytherapy? Effects of tissue trauma in an
experimental rat tumor model. Int J Radiat Oncol Biol Phys 2000;48:233-240.
)HKPVaHTHUP29>HSSULY2:\[SPLM:, et al. Anticipating prostatic volume changes due
to prostate brachytherapy. Radiat Oncol Investig 1999;7:360-364.
:VSOQLT 4* +H]PZ )1 7PZHUZR` ;4, et al. Prostate volume measurement by
transrectal ultrasound and computed tomography before and after permanent prostate
brachytherapy. Int J Radiat Oncol Biol Phys 2004;60:767-776.
>H[LYTHU-4@\L59LPZPUNLY:, et al. Effect of edema on the post-implant dosimetry
of an I-125 prostate implant: a case study. Int J Radiat Oncol Biol Phys 1997;38:335339.
76:;:*907;<4
76:;:*907;<4
Modelos clínico-dosimetricos en braquiterapia prostática
279.
281.
287.
290.
291.
292.
>H[LYTHU-4@\L5*VYU)>, et al.,KLTHHZZVJPH[LK^P[O0VY7KWYVZ[H[L
brachytherapy and its impact on post-implant dosimetry: an analysis based on serial
CT acquisition. Int J Radiat Oncol Biol Phys 1998;41:1069-1077.
7YLZ[PKNL )9 )PJL >: 2PLMLY ,1, et al. Timing of computed tomography-based
WVZ[PTWSHU[HZZLZZTLU[MVSSV^PUNWLYTHULU[[YHUZWLYPULHSWYVZ[H[LIYHJO`[OLYHW`Int
J Radiat Oncol Biol Phys 1998;40:1111-1115.
>PSSPUZ1>HSSULY2;PTLKLWLUKLU[JOHUNLZPU*;IHZLKKVZPTL[Y`VM0WYVZ[H[L
brachytherapy. Radiat Oncol Investig 1998;6:157-160.
4LYYPJR.:)\[SLY>4+VYZL`(;, et al.0UÅ\LUJLVM[PTPUNVU[OLKVZPTL[YPJHUHS`ZPZ
of transperineal ultrasound-guided, prostatic conformal brachytherapy. Radiat Oncol
Investig 1998;6:182-190.
+VNHU 5 4VOPKLLU 5 .SHZNV^ .7, et al. Effect of prostatic edema on CT-based
postimplant dosimetry. Int J Radiat Oncol Biol Phys 2002;53:483-489.
>H[LYTHU-4+PJRLY(70TWHJ[VMWVZ[PTWSHU[LKLTHVU=HUK+ PUWYVZ[H[L
brachytherapy: can implant quality be predicted on day 0? Int J Radiat Oncol Biol Phys
2002;53:610-621.
;H\ZZR` + (\Z[LU 3 ;VP (, et al. Sequential evaluation of prostate edema after
permanent seed prostate brachytherapy using CT-MRI fusion. Int J Radiat Oncol Biol
Phys 2005;62:974-980.
Moerland MA. The effect of edema on postimplant dosimetry of permanent iodine125 prostate implants: a simulation study. Journal of Brachytherapy Intenational
1998;14:225-231.
@\L5+PJRLY(7*VYU)>, et al. A dynamic model for the estimation of optimum timing
of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of
prostate. Int J Radiat Oncol Biol Phys 1999;43:447-454.
Yue N, Chen Z, Peschel R, et al. Optimum timing for image-based dose evaluation of
125I and 103PD prostate seed implants. Int J Radiat Oncol Biol Phys 1999;45:10631072.
)\[SLY>44LYYPJR.:+VYZL`(;, et al. Isotope choice and the effect of edema on
prostate brachytherapy dosimetry. Med Phys 2000;27:1067-1075.
*OLUA@\L5>HUN?, et al. Dosimetric effects of edema in permanent prostate seed
implants: a rigorous solution. Int J Radiat Oncol Biol Phys 2000;47:1405-1419.
-\RZA3LPILS:(>HSSULY2,, et al. The effect of local control on metastatic dissemination
PUJHYJPUVTHVM[OLWYVZ[H[L!SVUN[LYTYLZ\S[ZPUWH[PLU[Z[YLH[LK^P[O0PTWSHU[H[PVU
Int J Radiat Oncol Biol Phys 1991;21:537-547.
@VYRL,+-\RZA5VY[VU3, et al. Modeling the development of metastases from primary
HUKSVJHSS`YLJ\YYLU[[\TVYZ!JVTWHYPZVU^P[OHJSPUPJHSKH[HIHZLMVYWYVZ[H[PJJHUJLY
Cancer Res 1993;53:2987-2993.
:[VJR9.:[VUL55;HILY[(, et al. A dose-response study for I-125 prostate implants.
Int J Radiat Oncol Biol Phys 1998;41:101-108.
Potters L, Cao Y, Calugaru E, et al. ( JVTWYLOLUZP]L YL]PL^ VM *;IHZLK KVZPTL[Y`
WHYHTL[LYZ HUK IPVJOLTPJHS JVU[YVS PU WH[PLU[Z [YLH[LK ^P[O WLYTHULU[ WYVZ[H[L
brachytherapy. Int J Radiat Oncol Biol Phys 2001;50:605-614.
9P]HYK41*V\YZL`)4+L>LYK3(, et al.<WKH[LVM((74;HZR.YV\W5V9LWVY[!
A revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004;31:633674.
+LHZ`16)SHUJV(0*SHYR=/*,99!HJVTW\[H[PVUHSLU]PYVUTLU[MVYYHKPV[OLYHW`
research. Med Phys 2003;30:979-985.
El Naqa I, Suneja G, Lindsay PE, et al. Dose response explorer: an integrated open-source
tool for exploring and modelling radiotherapy dose-volume outcome relationships. Phys
Med Biol 2006;51:5719-5735.
El Naqa I, Bradley J, Blanco AI, et al. Multivariable modeling of radiotherapy outcomes,
including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys 2006;64:12751286.
Hope AJ, Lindsay PE, El Naqa I, et al.4VKLSPUNYHKPH[PVUWUL\TVUP[PZYPZR^P[OJSPUPJHS
dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 2006;65:112-124.
POSTSCRIPTUM
296.
299.
308.
Breinman L, Friedman JH, Olshen R, et al. *SHZZPÄJH[PVU HUK 9LNYLZZPVU ;YLLZ
4VU[LYL`*(!>HKZ^VY[O" +\UOHT 4 +H[H TPUPUN PU[YVK\J[VY` HUK HK]HUJLK [VWPJZ 5L^ 1LYZL`! 7LHYZVU
Education Inc.; 2003.
;HU7:[LPUIHJO42\THY=0U[YVK\J[PVU[VKH[HTPUPUN)VZ[VU!7LHYZVU,K\JH[PVU
Inc.; 2006.
Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic
factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int
J Radiat Oncol Biol Phys 1997;37:745-751.
.HZWHY3,:JV[[*4\YYH`2, et al. Validation of the RTOG recursive partitioning analysis
97(JSHZZPÄJH[PVUMVYIYHPUTL[HZ[HZLZInt J Radiat Oncol Biol Phys 2000;47:10011006.
*\YYHU>11Y:JV[[*)/VY[VU1, et al. Recursive partitioning analysis of prognostic
factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl
Cancer Inst 1993;85:704-710.
Scott CB, Scarantino C, Urtasun R, et al.=HSPKH[PVUHUKWYLKPJ[P]LWV^LYVM9HKPH[PVU
Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant
glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998;40:5155.
*VVWLY 1: )LYRL` ) 4HYJPHS =, et al. Validation of the RTOG recursive partitioning
JSHZZPÄJH[PVUMVYOLHKHUKULJR[\TVYZHead Neck 2001;23:669-677.
>LYULY>HZPR 4 :JV[[ * *V_ 1+, et al. Recursive partitioning analysis of 1999
9HKPH[PVU;OLYHW`6UJVSVN`.YV\W9;6.WH[PLU[Z^P[OSVJHSS`HK]HUJLKUVUZTHSS
JLSSS\UNJHUJLY3(5:*3*!PKLU[PÄJH[PVUVMÄ]LNYV\WZ^P[OKPMMLYLU[Z\Y]P]HSInt J
Radiat Oncol Biol Phys 2000;48:1475-1482.
2VTHRP9:JV[[*))`OHYK[9, et al. Failure patterns by prognostic group determined
by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy
oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J
Radiat Oncol Biol Phys 1998;42:263-267.
/LZZ 29 (IIY\aaLZL 4* 3LUaP 9, et al. *SHZZPÄJH[PVU HUK YLNYLZZPVU [YLL HUHS`ZPZ
VM JVUZLJ\[P]L WH[PLU[Z ^P[O \URUV^U WYPTHY` JHYJPUVTH Clin Cancer Res
1999;5:3403-3410.
;OVTHZ *9 1Y )LYRL` )( 4PUZR` )+, et al. Recursive partitioning analysis of
WYL[YLH[TLU[ ]HYPHISLZ VM WH[PLU[Z ^P[O SVJVYLNPVUHS LZVWOHNLHS JHUJLY [YLH[LK
^P[O KLÄUP[P]L JVUJVTP[HU[ JOLTVYHKPV[OLYHW` VU 0U[LYNYV\W HUK 9HKPH[PVU ;OLYHW`
Oncology Group trials. Int J Radiat Oncol Biol Phys 2004;58:1405-1410.
2H[a()\JOOVSa;(;OHTLZ/, et al. Recursive partitioning analysis of locoregional
YLJ\YYLUJL WH[[LYUZ MVSSV^PUN THZ[LJ[VT`! PTWSPJH[PVUZ MVY HKQ\]HU[ PYYHKPH[PVU Int J
Radiat Oncol Biol Phys 2001;50:397-403.
-YLLKTHU.4/HUSVU(3-V^ISL)3, et al.9LJ\YZP]LWHY[P[PVUPUNPKLU[PÄLZWH[PLU[Z
H[OPNOHUKSV^YPZRMVYPWZPSH[LYHS[\TVYYLJ\YYLUJLHM[LYIYLHZ[JVUZLY]PUNZ\YNLY`HUK
radiation. J Clin Oncol 2002;20:4015-4021.
AOHUN/@\*@:PUNLY)*LSSHUK[\TVYJSHZZPÄJH[PVU\ZPUNNLULL_WYLZZPVUKH[H!
construction of forests. Proc Natl Acad Sci U S A 2003;100:4168-4172.
Zhang H, Yu CY, Singer B, et al.9LJ\YZP]LWHY[P[PVUPUNMVY[\TVYJSHZZPÄJH[PVU^P[ONLUL
expression microarray data. Proc Natl Acad Sci U S A 2001;98:6730-6735.
2H^HRHTP:/`VJOP5@VULZL1, et al. Three-dimensional combination of transrectal
HUK[YHUZWLYPULHSIPVWZPLZMVYLMÄJPLU[KL[LJ[PVUVMZ[HNL;JWYVZ[H[LJHUJLYInt J Clin
Oncol 2006;11:127-132.
2H^HRHTP : 6R\UV ; @VULZL 1, et al. Optimal Sampling Sites for Repeat Prostate
Biopsy: A Recursive Partitioning Analysis of Three-Dimensional 26-Core Systematic
Biopsy. Eur Urol 2006.
*OL\UN 9 ;\JRLY :3 2\IHU +( -PYZ[`LHY 7:( RPUL[PJZ HUK TPUPTH HM[LY WYVZ[H[L
cancer radiotherapy are predictive of overall survival. Int J Radiat Oncol Biol Phys
2006;66:20-24.
*OL\UN 9 ;\JRLY :3 +VUN 3, et al. Dose-response for biochemical control among
76:;:*907;<4
293.
76:;:*907;<4
Modelos clínico-dosimetricos en braquiterapia prostática
315.
325.
326.
327.
332.
OPNOYPZRWYVZ[H[LJHUJLYWH[PLU[ZHM[LYL_[LYUHSILHTYHKPV[OLYHW`Int J Radiat Oncol
Biol Phys 2003;56:1234-1240.
;OHTLZ/+2\IHU+(+L:PS]PV43, et al. Increasing external beam dose for T1-T2
WYVZ[H[LJHUJLY!LMMLJ[VUYPZRNYV\WZInt J Radiat Oncol Biol Phys 2006;65:975-981.
/VY^P[a ,4 /HUSVU (3 7PUV]LY >/, et al. +LÄUPUN [OL VW[PTHS YHKPH[PVU KVZL ^P[O
[OYLLKPTLUZPVUHSJVUMVYTHSYHKPH[PVU[OLYHW`MVYWH[PLU[Z^P[OUVUTL[HZ[H[PJWYVZ[H[L
carcinoma by using recursive partitioning techniques. Cancer 2001;92:1281-1287.
Gretzer MB, Epstein JI, Pound CR, et al.:\IZ[YH[PÄJH[PVUVMZ[HNL;*WYVZ[H[LJHUJLY
based on the probability of biochemical recurrence. Urology 2002;60:1034-1039.
>PSSPHTZ:.4PSSHY13+HSS`41, et al.>OH[KLÄULZPU[LYTLKPH[LYPZRWYVZ[H[LJHUJLY&
Variability in published prognostic models. Int J Radiat Oncol Biol Phys 2004;58:1118.
)HULYQLL4)PZ^HZ+:HRY>, et al. Recursive partitioning for prognostic grouping of
WH[PLU[Z^P[OJSPUPJHSS`SVJHSPaLKWYVZ[H[LJHYJPUVTHCancer 2000;89:404-411.
>PSSPHTZ :. +\JOLZUL .4 .VNUH 52, et al. An international multicenter study
L]HS\H[PUN[OLPTWHJ[VMHUHS[LYUH[P]LIPVJOLTPJHSMHPS\YLKLÄUP[PVUVU[OLQ\KNTLU[VM
WYVZ[H[LJHUJLYYPZRInt J Radiat Oncol Biol Phys 2006;65:351-357.
:O\STHU 41 )LUHPT ,( 7YVNUVZ[PJ TVKLS VM L]LU[MYLL Z\Y]P]HS MVY WH[PLU[Z ^P[O
androgen-independent prostate carcinoma. Cancer 2005;103:2280-2286.
7HWPR 2 4VSUHY ) :JOHLMLY 9, et al. (WWSPJH[PVU VM UL\YHS UL[^VYRZ PU TLKPJPUL H
YL]PL^Medical Science Monitor 1998;4:538-546.
9LKKPJR>,4\SOLYU92,SRPU;+, et al.(O`IYPKUL\YHSUL[^VYRHUHS`ZPZVMZ\I[SL
brain volume differences in children surviving brain tumors. Magn Reson Imaging
1998;16:413-421.
:VUN1/=LURH[LZO::*VUHU[,(, et al. Comparative analysis of logistic regression
HUK HY[PÄJPHS UL\YHS UL[^VYR MVY JVTW\[LYHPKLK KPHNUVZPZ VM IYLHZ[ THZZLZ Acad
Radiol 2005;12:487-495.
7YH[LY 1: 9PJOHYK >+ :LNTLU[PUN \S[YHZV\UK PTHNLZ VM [OL WYVZ[H[L \ZPUN UL\YHS
UL[^VYRZUltrason Imaging 1992;14:159-185.
9H]KPU74*SHYR.4(WYHJ[PJHSHWWSPJH[PVUVMUL\YHSUL[^VYRHUHS`ZPZMVYWYLKPJ[PUN
outcome of individual breast cancer patients. Breast Cancer Res Treat 1992;22:285293.
Floyd CE, Jr., Lo JY, Yun AJ, et al. Prediction of breast cancer malignancy using an
HY[PÄJPHSUL\YHSUL[^VYRCancer 1994;74:2944-2948.
Jerez-Aragones JM, Gomez-Ruiz JA, Ramos-Jimenez G, et al. A combined neural
UL[^VYR HUK KLJPZPVU [YLLZ TVKLS MVY WYVNUVZPZ VM IYLHZ[ JHUJLY YLSHWZL Artif Intell
Med 2003;27:45-63.
Biganzoli E, Boracchi P, Coradini D, et al. Prognosis in node-negative primary breast
JHUJLY!HUL\YHSUL[^VYRHUHS`ZPZVMYPZRWYVÄSLZ\ZPUNYV\[PULS`HZZLZZLKMHJ[VYZAnn
Oncol 2003;14:1484-1493.
)Y`JL;1+L^OPYZ[4>-SV`K*,1Y, et al.(Y[PÄJPHSUL\YHSUL[^VYRTVKLSVMZ\Y]P]HSPU
WH[PLU[Z[YLH[LK^P[OPYYHKPH[PVU^P[OHUK^P[OV\[JVUJ\YYLU[JOLTV[OLYHW`MVYHK]HUJLK
JHYJPUVTHVM[OLOLHKHUKULJRInt J Radiat Oncol Biol Phys 1998;41:339-345.
:\44PM[LU4>OPKKVU*, et al.(UHY[PÄJPHSUL\YHSUL[^VYRMVYWYLKPJ[PUN[OLPUJPKLUJL
of radiation pneumonitis. Med Phys 2005;32:318-325.
(UHNUVZ[V\ ; 9LTaP 4 3`RV\YPUHZ 4, et al. (Y[PÄJPHS UL\YHS UL[^VYRZ MVY KLJPZPVU
THRPUNPU\YVSVNPJVUJVSVN`Eur Urol 2003;43:596-603.
:HYNLU[+1*VTWHYPZVUVMHY[PÄJPHSUL\YHSUL[^VYRZ^P[OV[OLYZ[H[PZ[PJHSHWWYVHJOLZ!
results from medical data sets. Cancer 2001;91:1636-1642.
Finne P, Finne R, Auvinen A, et al. Predicting the outcome of prostate biopsy in screenWVZP[P]LTLUI`HT\S[PSH`LYWLYJLW[YVUUL[^VYRUrology 2000;56:418-422.
2HSYH7;VNHTP1)HUZHS):., et al. A neurocomputational model for prostate carcinoma
detection. Cancer 2003;98:1849-1854.
/HU 4 :UV^ 7) )YHUK[ 14, et al. ,]HS\H[PVU VM HY[PÄJPHS UL\YHS UL[^VYRZ MVY [OL
prediction of pathologic stage in prostate carcinoma. Cancer 2001;91:1661-1666.
4H[[MLSK[;2LZ[SLY/(/H\[THUU9, et al. Prediction of prostatic cancer progression
POSTSCRIPTUM
347.
352.
76:;:*907;<4
336.
HM[LYYHKPJHSWYVZ[H[LJ[VT`\ZPUNHY[PÄJPHSUL\YHSUL[^VYRZ!HMLHZPIPSP[`Z[\K`BJU Int
1999;84:316-323.
Potter SR, Miller MC, Mangold LA, et al. .LUL[PJHSS` LUNPULLYLK UL\YHS UL[^VYRZ
for predicting prostate cancer progression after radical prostatectomy. Urology
1999;54:791-795.
/HU4:UV^7),WZ[LPU10, et al.(UL\YHSUL[^VYRWYLKPJ[ZWYVNYLZZPVUMVYTLU^P[O
gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology 2000;56:994999.
.\SSPMVYK:3>LII:9V^IV[[VT*., et al.<ZLVMHY[PÄJPHSUL\YHSUL[^VYRZ[VWYLKPJ[
biological outcomes for patients receiving radical radiotherapy of the prostate. Radiother
Oncol 2004;71:3-12.
/HU 4 7HY[PU (> 7PHU[HKVZP :, et al. ,YH ZWLJPÄJ IPVJOLTPJHS YLJ\YYLUJLMYLL
Z\Y]P]HSMVSSV^PUNYHKPJHSWYVZ[H[LJ[VT`MVYJSPUPJHSS`SVJHSPaLKWYVZ[H[LJHUJLYJ Urol
2001;166:416-419.
:LUN\W[H::SLaHR14)S\[L43, et al.;YLUKZPUKPZ[YPI\[PVUHUKWYVNUVZ[PJZPNUPÄJHUJL
VM.SLHZVUNYHKLZVUYHKPJHSYL[YVW\IPJWYVZ[H[LJ[VT`ZWLJPTLUZIL[^LLU HUK
2001. Cancer 2006;106:2630-2635.
AHNHYZ.2(`HSH(.]VU,ZJOLUIHJO(*, et al. The prognostic importance of Gleason
NYHKLPUWYVZ[H[PJHKLUVJHYJPUVTH!HSVUN[LYTMVSSV^\WZ[\K`VMWH[PLU[Z[YLH[LK
^P[OYHKPH[PVU[OLYHW`Int J Radiat Oncol Biol Phys 1995;31:237-245.
>VUN>>:JOPSK:,=VYH:(, et al. Association of percent positive prostate biopsies
HUKWLYPUL\YHSPU]HZPVU^P[OIPVJOLTPJHSV\[JVTLHM[LYL_[LYUHSILHTYHKPV[OLYHW`MVY
localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;60:24-29.
=PJPUP-(/VY^P[a,42PUP=9, et al. Radiotherapy options for localized prostate cancer
IHZLK\WVUWYL[YLH[TLU[ZLY\TWYVZ[H[LZWLJPÄJHU[PNLUSL]LSZHUKIPVJOLTPJHSJVU[YVS!
HJVTWYLOLUZP]LYL]PL^VM[OLSP[LYH[\YLInt J Radiat Oncol Biol Phys 1998;40:11011110.
=PJPUP -( 2PUP =9 ,KT\UKZVU ., et al. ( JVTWYLOLUZP]L YL]PL^ VM WYVZ[H[L JHUJLY
IYHJO`[OLYHW`!KLÄUPUNHUVW[PTHS[LJOUPX\LInt J Radiat Oncol Biol Phys 1999;44:483491.
1VULZ;+2VJO46)\UKL71, et al.0ZWYVZ[H[LZWLJPÄJHU[PNLU7:(KLUZP[`IL[[LY
than the preoperative PSA level in predicting early biochemical recurrence of prostate
cancer after radical prostatectomy? BJU Int 2006;97:480-484.
7V[[LYZ3*OH*6ZOPUZR`., et al.9PZRWYVÄSLZ[VWYLKPJ[7:(YLSHWZLMYLLZ\Y]P]HSMVY
patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999;5:301306.
Potters L, Torre T, Ashley R, et al. Examining the role of neoadjuvant androgen deprivation
in patients undergoing prostate brachytherapy. J Clin Oncol 2000;18:1187-1192.
4LYYPJR.:)\[SLY>4.HSIYLH[O9>, et al.-P]L`LHYIPVJOLTPJHSV\[JVTLMVSSV^PUN
permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat
Oncol Biol Phys 2001;51:41-48.
4LYYPJR.:)\[SLY>4.HSIYLH[O9>, et al. Does hormonal manipulation in conjunction
^P[OWLYTHULU[PU[LYZ[P[PHSIYHJO`[OLYHW`^P[OVY^P[OV\[Z\WWSLTLU[HSL_[LYUHSILHT
PYYHKPH[PVU PTWYV]L [OL IPVJOLTPJHS V\[JVTL MVY TLU ^P[O PU[LYTLKPH[L VY OPNOYPZR
prostate cancer? BJU Int 2003;91:23-29.
3LL 35 :[VJR 9. :[VUL 55 9VSL VM OVYTVUHS [OLYHW` PU [OL THUHNLTLU[ VM
PU[LYTLKPH[L [V OPNOYPZR WYVZ[H[L JHUJLY [YLH[LK ^P[O WLYTHULU[ YHKPVHJ[P]L ZLLK
implantation. Int J Radiat Oncol Biol Phys 2002;52:444-452.
)L`LY+*4J2LV\NO;;OVTHZ;0TWHJ[VMZOVY[JV\YZLOVYTVUHS[OLYHW`VUV]LYHSS
HUKJHUJLYZWLJPÄJZ\Y]P]HSHM[LYWLYTHULU[WYVZ[H[LIYHJO`[OLYHW`Int J Radiat Oncol
Biol Phys 2005;61:1299-1305.
Ash D, Al-Qaisieh B, Bottomley D, et al. The impact of hormone therapy on postPTWSHU[KVZPTL[Y`HUKV\[JVTLMVSSV^PUN0VKPULPTWSHU[TVUV[OLYHW`MVYSVJHSPZLK
prostate cancer. Radiother Oncol 2005;75:303-306.
*YVVR14J3LHU4@L\UN0, et al. MRI-CT fusion to assess postbrachytherapy prostate
]VS\TL HUK [OL LMMLJ[Z VM WYVSVUNLK LKLTH VU KVZPTL[Y` MVSSV^PUN [YHUZWLYPULHS
76:;:*907;<4
Modelos clínico-dosimetricos en braquiterapia prostática
357.
359.
365.
367.
368.
369.
371.
interstitial permanent prostate brachytherapy. Brachytherapy 2004;3:55-60.
4J3H\NOSPU7>5HYH`HUH=2LZZSLY4, et al. The use of mutual information in registration
of CT and MRI datasets post permanent implant. Brachytherapy 2004;3:61-70.
9LLK+9>HSSULY2-VYK,, et al. Effect of post-implant edema on prostate brachytherapy
treatment margins. Int J Radiat Oncol Biol Phys 2005;63:1469-1473.
4LYYPJR .: )\[SLY >4 +VYZL` (;, et al. Potential role of various dosimetric quality
indicators in prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;44:717-724.
McLaughlin P, Narayana V, Pan C, et al. Comparison of day 0 and day 14 dosimetry
for permanent prostate implants using stranded seeds. Int J Radiat Oncol Biol Phys
2006;64:144-150.
:[VJR9.:[VUL553V@*, et al. Postimplant dosimetry for (125)I prostate implants:
KLÄUP[PVUZHUKMHJ[VYZHMMLJ[PUNV\[JVTLInt J Radiat Oncol Biol Phys 2000;48:899906.
Ash D, Al-Qaisieh B, Bottomley D, et al. ;OL JVYYLSH[PVU IL[^LLU + HUK V\[JVTL
for I-125 seed implant monotherapy for localised prostate cancer. Radiother Oncol
2006;79:185-189.
9VILY[3LL>+LN\aTHU(-4J4\SSLU27, et al. Dosimetry and cancer control after
SV^KVZLYH[LWYVZ[H[LIYHJO`[OLYHW`Int J Radiat Oncol Biol Phys 2005;61:52-59.
7HWHNPRVZ4(+LN\aTHU(-9VZZP71, et al.+VZPTL[YPJX\HU[PÄLYZMVYSV^KVZLYH[L
prostate brachytherapy: is V(100) superior to D(90)? Brachytherapy 2005;4:252-258.
*OL\UN 9 ;\JRLY :3 3LL (2, et al. +VZLYLZWVUZL JOHYHJ[LYPZ[PJZ VM SV^ HUK
PU[LYTLKPH[LYPZRWYVZ[H[LJHUJLY[YLH[LK^P[OL_[LYUHSILHTYHKPV[OLYHW`Int J Radiat
Oncol Biol Phys 2005;61:993-1002.
3L]LNY\U:1HJRZVU(ALSLMZR`41, et al. Fitting tumor control probability models to
biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer:
pitfalls in deducing radiobiologic parameters for tumors from clinical data. Int J Radiat
Oncol Biol Phys 2001;51:1064-1080.
2PUN *9 3+9 ]Z /+9 IYHJO`[OLYHW` MVY SVJHSPaLK WYVZ[H[L JHUJLY! [OL ]PL^ MYVT
radiobiological models. Brachytherapy 2002;1:219-226.
Moriguchi S, Hayashi Y, Nose Y, et al. A comparison of the logistic regression and the
Cox proportional hazard models in retrospective studies on the prognosis of patients
^P[ONHZ[YPJJHUJLYJ Surg Oncol 1993;52:9-13.
=PY[HULU ( .VTHYP 4 2YHUZL 9, et al. Estimation of prostate cancer probability by
SVNPZ[PJYLNYLZZPVU!MYLLHUK[V[HSWYVZ[H[LZWLJPÄJHU[PNLUKPNP[HSYLJ[HSL_HTPUH[PVU
HUKOLYLKP[`HYLZPNUPÄJHU[]HYPHISLZClin Chem 1999;45:987-994.
Aslam N, Banerjee S, Carr JV, et al. Prospective evaluation of logistic regression models
for the diagnosis of ovarian cancer. Obstet Gynecol 2000;96:75-80.
Lumachi F, Ermani M, Brandes AA, et al. Predictive value of different prognostic factors
in breast cancer recurrences: multivariate analysis using a logistic regression model.
Anticancer Res 2001;21:4105-4108.
Forman JD, Duclos M, Shamsa F, et al. Predicting the need for adjuvant systemic
therapy in patients receiving postprostatectomy irradiation. Urology 1996;47:382-386.
3L]LNY\U : 1HJRZVU ( ALSLMZR` 41, et al. Analysis of biopsy outcome after threedimensional conformal radiation therapy of prostate cancer using dose-distribution
variables and tumor control probability models. Int J Radiat Oncol Biol Phys
2000;47:1245-1260.
Zapatero A, Garcia-Vicente F, Modolell I, et al. Impact of mean rectal dose on late rectal
bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Int J
Radiat Oncol Biol Phys 2004;59:1343-1351.
7PZHUZR` ;4 )S\[L 43 /PSSTHU +>, et al. ;OL YLSL]HUJL VM WYVZ[H[LJ[VT` ÄUKPUNZ
MVY IYHJO`[OLYHW` ZLSLJ[PVU PU WH[PLU[Z ^P[O SVJHSPaLK WYVZ[H[L JHYJPUVTH Cancer
2002;95:513-519.
:OPWSL`><;OHTLZ/+:HUKSLY/4, et al. Radiation therapy for clinically localized
prostate cancer: a multi-institutional pooled analysis. Jama 1999;281:1598-1604.
;ZPLU*3-YHZLY/:3VUN>1, et al.<ZPUNJSHZZPÄJH[PVU[YLLHUKSVNPZ[PJYLNYLZZPVU
methods to diagnose myocardial infarction. Medinfo 1998;9 Pt 1:493-497.
POSTSCRIPTUM
4VU[PL1,>LP1;(Y[PÄJPHSUL\YHSUL[^VYRZMVYWYVZ[H[LJHYJPUVTHYPZRHZZLZZTLU[(U
V]LY]PL^Cancer 2001;91:1647-1652.
=LS[YP9>*OH\KOHYP44PSSLY4*, et al. Comparison of logistic regression and neural net
modeling for prediction of prostate cancer pathologic stage. Clin Chem 2002;48:18281834.
7VY[LY * 6»+VUULSS * *YH^MVYK ,+, et al. (Y[PÄJPHS UL\YHS UL[^VYR TVKLS [V WYLKPJ[
biochemical failure after radical prostatectomy. Mol Urol 2001;5:159-162.
76:;:*907;<4